Future of Mental Health: Can Psychedelics Fix What Antidepressants Can’t?
Tomi Lahren tackles the mental health crisis on why treatment rather than lifelong meds is so important. Cybin CEO, Doug Drysdale, joins to share his breakthrough psychedelic therapy and what it means for those struggling today.
Learn more about your ad choices. Visit podcastchoices.com/adchoices
Cybin CEO Doug Drysdale On What Distinguishes CYB003 from Other Aspiring Novel Depression Treatments
Send us Fan Mail
In our latest WTR Small-Cap Spotlight x Healthcare Crossover, Cybin CEO Doug Drysdale joins Water Tower Research’s Tim Gerdeman and Senior Analyst Robert Sassoon to discuss the company's non-traditional financing strategy as it continues to advance its development pipeline. Drysdal…
Cybin CEO Doug Drysdale On What Distinguishes CYB003 from Other Aspiring Novel Depression Treatments
In our first rebranded WTR Healthcare Spotlight, Cybin CEO Doug Drysdale joins Water Tower Research’s Tim Gerdeman and Senior Analyst Robert Sassoon to discuss the company's non-traditional financing strategy as it continues to advance its development pipeline. Drysdale also probes into data that h…
Doug Drysdale on Advancing Psychedelic Medicine for Mental Health Treatment
In this Mission Matters episode, Adam Torres interviews Doug Drysdale, CEO of Cybin, about the groundbreaking work his company is doing to develop psychedelic-based treatments for mental health conditions. From clinical trials to regulatory challenges, Doug shares his mission to transform suff…
Meet the biopharma CEO who’s bullish on psychedelic-assisted therapies
Just over two years ago, the FDA issued its first draft guidance on clinical trials with psychedelic drugs. Now, HHS has hired a dedicated psychedelics advisor.
This week, Reunion Neuroscience reported a mid-stage success with its short-acting psychedelic drug in postpartum depression.
At a moment…
Doug Drysdale on Advancing Psychedelic Medicine for Mental Health Treatment
In this Mission Matters episode, Adam Torres interviews Doug Drysdale, CEO of Cybin, about the groundbreaking work his company is doing to develop psychedelic-based treatments for mental health conditions. From clinical trials to regulatory challenges, Doug shares his mission to transform sufferin…
Going All In on Psilocybin for Depression
In this episode, we sit down with Doug Drysdale, CEO of Cybin, to discuss the growing interest in psilocybin as a potential treatment for depression and other mental health conditions. Doug talks candidly about his initial skepticism and how the data convinced him to dive into the world of psychede…
Building the Future of BIOTECH, with Doug Drysdale, former CEO of Cybin (Helus Pharma)
In this exclusive interview, veteran biotech executive Doug Drysdale sits down with Jason Najum from Pink Elephant to discuss the strategy that steered Cybin through the 'biotech winter.' Although Doug stepped down as CEO in September 2025 and the company has since rebranded to Helus Pharma, his in…
The Psychedelic Inflection Point: Big Pharma, FDA, and the Next Wave of Brain Medicines
In this episode of WTR Healthcare Happenings, Doug Drysdale, biopharma veteran and founder of Katagen, former CEO of Cybin (now Helus Pharma), joins WTR's Tim Gerdeman and analyst Robert Sassoon to explore whether psychedelic medicine has moved from speculative niche to mainstream therapeutic categ…
MESIN PENCARI PODCAST
Anda dapat menggunakan situs web kami untuk mencari podcast3,830,558dan episode196,657,032menurut orang, tempat, atau topik.
Investasi dalam pengetahuan memberikan hasil terbaik, jadi saya mendengarkan podcast.
‐ Benjamin "Llamacorn" Franklin
Sunting
Terima kasih telah membantu agar basis data podcast tetap terbaru
